Market Cap 6.77M
Revenue (ttm) 170,000.00
Net Income (ttm) -17.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,188.24%
Debt to Equity Ratio 0.00
Volume 14,300
Avg Vol 204,546
Day's Range N/A - N/A
Shares Out 2.71M
Stochastic %K 52%
Beta 0.98
Analysts Sell
Price Target $6.00

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
Aimforsuccess
Aimforsuccess Sep. 17 at 9:05 PM
$AIM In my opinion the naked shorts are financial terrorists. Management has provided them a winning hand for years. Patient welfare has no place in their world.
1 · Reply
TheLionofwallstreet
TheLionofwallstreet Sep. 17 at 5:17 PM
$SLS I feel Like over the years watching this and $AIM these two companies are being suppressed by Big Pharma. Great drugs with awesome data, safety, and patents to back them. Bp is doing all they can to make sure the drugs never hit the market. Sad for the investors and even worse for the patients who could benefit from having the drugs available. ... Eventually if they are unable to bankrupt the companies they will buy them out for pennies and most likely never let the drugs see the light of day so that they can continue to peddle their drugs that make them more money and still have less effectiveness so that they can continue to suck the blood out of their dying clientele all while feeding the healthy people things that will eventually have them sick enough to go see the dr and get prescriptions that only keep them alive long enough to empty that bank account.
3 · Reply
uuddlrlr
uuddlrlr Sep. 15 at 9:32 PM
$AIM Video presentation. AIM's section starts around minute 40. - Three companies present in this video...unfortunately (IMO) CEO Equels was the weakest https://www.webull.com/learn/courseware/JPqP7g/Corporate-Connect-Webinar-Series-Biotech-Medtech-Week-Day-2
2 · Reply
ultimatebastos
ultimatebastos Sep. 15 at 6:19 PM
$AIM the shorts have robbed retailors clean yes jurkjurkson is one of them. But that is not the end of the. In the end they will poor all they stole in the pockets of management and the new big holders. Retailers will be left in the cold but it will be so nice to see the shorts burn like never before.
1 · Reply
jonjonson1234
jonjonson1234 Sep. 15 at 4:49 PM
$AIM Short interest in the company remains trivial Shares Outstanding 2.71M Float 2.59M % Held by Insiders 3.42% % Held by Institutions 1.68% Shares Short (8/29/2025) 37.39k Short % of Float (8/29/2025) 1.42% Short % of Shares Outstanding (8/29/2025) 1.38% There are some posters here who prefer to remain willfully and stubbornly ignorant of the fact that when a company is actively dumping new shares onto the market, as $AIM does through its at-the-market share dumping scheme with Maxim, that the shares appear of the Reg-SHO data because of the mechanics of how the market makers make such trades. They instead prefer to squawk about all of the imaginary "naked shorts." When the company was temporarily delisted, and the Maxim deal was thus on hold, all of the "naked shorting" went away. As soon as they were relisted and could resume dumping shares at-the-market suddenly the number of shares turning up on Reg SHO popped up.
1 · Reply
Chessdoc
Chessdoc Sep. 15 at 11:40 AM
$AIM This sounds right up AIM‘s alley: https://scitechdaily.com/new-mrna-cancer-vaccine-delivers-stunning-results-sparks-universal-treatment-hopes/
2 · Reply
ultimatebastos
ultimatebastos Sep. 14 at 4:47 PM
$AIM naked shorting is stalling Maby good news on the way.
0 · Reply
ultimatebastos
ultimatebastos Sep. 14 at 4:29 PM
$AIM if they don’t make a deal and keep paying those disgusting high management salaries without changing then the cash will be gone in a year. They really help the shorts rob investors. But I still believe in the force of Ampligen!
0 · Reply
ultimatebastos
ultimatebastos Sep. 12 at 7:30 PM
$AIM 1,231,440 deaths in the us The first number could have been lost if they had deployed Ampligen to fight Covid And let’s not forget the people suffering long covid who survived….
0 · Reply
CyrusTrade
CyrusTrade Sep. 12 at 5:19 PM
$AIM how are they operating without cash. I read in last 10Q that they had 450k cash with 2.5m burn/Q? Have they raised any cash since Jun30?
1 · Reply
Latest News on AIM
AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 27 days ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment


Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 28, 2025, 11:12 AM EDT - 7 weeks ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?


AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 3 months ago

AIM ImmunoTech Resumes Trading on NYSE American


AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 3 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split


Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:54 AM EDT - 4 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript


AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 9:19 AM EDT - 6 months ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript


Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 6 months ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript


AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Dec 11, 2024, 7:30 AM EST - 10 months ago

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed


AIM ImmunoTech Announces Cash Conservation Plan

Nov 27, 2024, 8:00 AM EST - 10 months ago

AIM ImmunoTech Announces Cash Conservation Plan


AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 10:32 AM EST - 10 months ago

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript


Aimforsuccess
Aimforsuccess Sep. 17 at 9:05 PM
$AIM In my opinion the naked shorts are financial terrorists. Management has provided them a winning hand for years. Patient welfare has no place in their world.
1 · Reply
TheLionofwallstreet
TheLionofwallstreet Sep. 17 at 5:17 PM
$SLS I feel Like over the years watching this and $AIM these two companies are being suppressed by Big Pharma. Great drugs with awesome data, safety, and patents to back them. Bp is doing all they can to make sure the drugs never hit the market. Sad for the investors and even worse for the patients who could benefit from having the drugs available. ... Eventually if they are unable to bankrupt the companies they will buy them out for pennies and most likely never let the drugs see the light of day so that they can continue to peddle their drugs that make them more money and still have less effectiveness so that they can continue to suck the blood out of their dying clientele all while feeding the healthy people things that will eventually have them sick enough to go see the dr and get prescriptions that only keep them alive long enough to empty that bank account.
3 · Reply
uuddlrlr
uuddlrlr Sep. 15 at 9:32 PM
$AIM Video presentation. AIM's section starts around minute 40. - Three companies present in this video...unfortunately (IMO) CEO Equels was the weakest https://www.webull.com/learn/courseware/JPqP7g/Corporate-Connect-Webinar-Series-Biotech-Medtech-Week-Day-2
2 · Reply
ultimatebastos
ultimatebastos Sep. 15 at 6:19 PM
$AIM the shorts have robbed retailors clean yes jurkjurkson is one of them. But that is not the end of the. In the end they will poor all they stole in the pockets of management and the new big holders. Retailers will be left in the cold but it will be so nice to see the shorts burn like never before.
1 · Reply
jonjonson1234
jonjonson1234 Sep. 15 at 4:49 PM
$AIM Short interest in the company remains trivial Shares Outstanding 2.71M Float 2.59M % Held by Insiders 3.42% % Held by Institutions 1.68% Shares Short (8/29/2025) 37.39k Short % of Float (8/29/2025) 1.42% Short % of Shares Outstanding (8/29/2025) 1.38% There are some posters here who prefer to remain willfully and stubbornly ignorant of the fact that when a company is actively dumping new shares onto the market, as $AIM does through its at-the-market share dumping scheme with Maxim, that the shares appear of the Reg-SHO data because of the mechanics of how the market makers make such trades. They instead prefer to squawk about all of the imaginary "naked shorts." When the company was temporarily delisted, and the Maxim deal was thus on hold, all of the "naked shorting" went away. As soon as they were relisted and could resume dumping shares at-the-market suddenly the number of shares turning up on Reg SHO popped up.
1 · Reply
Chessdoc
Chessdoc Sep. 15 at 11:40 AM
$AIM This sounds right up AIM‘s alley: https://scitechdaily.com/new-mrna-cancer-vaccine-delivers-stunning-results-sparks-universal-treatment-hopes/
2 · Reply
ultimatebastos
ultimatebastos Sep. 14 at 4:47 PM
$AIM naked shorting is stalling Maby good news on the way.
0 · Reply
ultimatebastos
ultimatebastos Sep. 14 at 4:29 PM
$AIM if they don’t make a deal and keep paying those disgusting high management salaries without changing then the cash will be gone in a year. They really help the shorts rob investors. But I still believe in the force of Ampligen!
0 · Reply
ultimatebastos
ultimatebastos Sep. 12 at 7:30 PM
$AIM 1,231,440 deaths in the us The first number could have been lost if they had deployed Ampligen to fight Covid And let’s not forget the people suffering long covid who survived….
0 · Reply
CyrusTrade
CyrusTrade Sep. 12 at 5:19 PM
$AIM how are they operating without cash. I read in last 10Q that they had 450k cash with 2.5m burn/Q? Have they raised any cash since Jun30?
1 · Reply
Paristommy
Paristommy Sep. 11 at 2:10 PM
$AIM Where is our fearless leader? My guess he’ll crawl out of his hole in November, when it’s time to beg for votes !!
2 · Reply
ultimatebastos
ultimatebastos Sep. 11 at 6:54 AM
$AIM Lets hope the shorters who brought the company in this stat make it to court to deserve their iron bar cages
0 · Reply
Jaortiz
Jaortiz Sep. 10 at 6:30 PM
$AIM tom destroyed us with the rs . Basically are sitting at .02 . I remember getting in at $2.20 thinking it was a good deal 🙄. TOM SHOULD BE FIRED
5 · Reply
yolotothemooon
yolotothemooon Sep. 9 at 4:21 PM
$AIM my guess is thursday and friday the september 12th aim is a truth rocket to the moon
2 · Reply
uuddlrlr
uuddlrlr Sep. 8 at 4:08 PM
$AIM In Nov 2024, AIM announced the a "cash conservation plan" where BOD members would be paid in stock. - "Effective immediately, AIM’s independent directors will receive 100% of their Board compensation in shares of the Company’s common stock. They will not receive any director compensation in cash. In lieu of cash payments, each independent director will receive twice a month stock grants, at a valuation equal to the closing price of AIM shares on the last trading day before such grants are made." These transactions to the BOD were being reported in SEC Form 4 but appear to have stopped after March 2025. Did AIM communicate a change to BOD compensation that would have ceased the Form 4 transactions?
2 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 9:53 AM
$AIM Outstanding article that hits the mark on AIM's current state. So if you want to refresh your AIM insights or learn about AIM from scratch, this is a must read. https://beyondspx.com/quote/AIM/analysis/aim-immunotech-unlocking-immunotherapy-s-potential-amidst-financial-headwinds-nyse-american-aim
0 · Reply
ultimatebastos
ultimatebastos Sep. 7 at 7:17 AM
$AIM all I need more is Aim to make it.
2 · Reply
ultimatebastos
ultimatebastos Sep. 5 at 8:33 PM
$AIM https://www.yahoo.com/news/articles/chief-lifts-global-mpox-emergency-160817163.html
1 · Reply
BioTuesdays
BioTuesdays Sep. 5 at 4:58 PM
$AIM announced the latest in a growing body of positive data from its lead clinical program, Ampligen, for the treatment of pancreatic cancer (PC), in a presentation at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland. https://biotuesdays.com/2025/09/05/aim-highlights-compelling-data-for-ampligen-in-pc-at-conference-in-poland/
0 · Reply
ultimatebastos
ultimatebastos Sep. 5 at 2:41 PM
$AIM there is only one sollution for Ebola and that is Ampligen. I hope they won’t use the duds the used last time…
2 · Reply
ultimatebastos
ultimatebastos Sep. 5 at 2:35 PM
$AIM https://www.nytimes.com/2025/09/04/world/africa/congo-ebola-outbreak.html
0 · Reply
ultimatebastos
ultimatebastos Sep. 5 at 2:34 PM
$AIM https://www.yahoo.com/news/articles/congo-declares-ebola-outbreak-three-134443856.html
0 · Reply